Zydus Lifesciences reports strong Q3 & 9M FY26 growth
Revenue from operations surged 30% year-on-year to Rs. 68,645 million
Revenue from operations surged 30% year-on-year to Rs. 68,645 million
Launched in August 2025, GSK India’s Oncology business is rapidly gaining momentum
The unveiling marks Time Medical India’s entry into next-generation helium-free MRI technology
LIVMARLI’s new tablet form offers patients weighing 22 kg or more a convenient, one-tablet-per-dose option, complementing the existing 9.5 mg/ml oral solution
The board highlighted ongoing investments in Radiopharma, CDMO Sterile Injectables, and CRDMO businesses
HCG clinicians contributing to one of the largest bodies of oncology research from India
Pfizer’s anti-infectives portfolio includes both established therapies for moderate to severe infections and newer, clinically robust antimicrobial treatments
The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer
Call it one of the most striking turnarounds in the Indian pharma sector this fiscal year
Subscribe To Our Newsletter & Stay Updated